CD19 and interstitial lung disease: A subsequent case of a 38-year-old woman with rapid progressive Scl70 + systemic sclerosis-associated interstitial lung disease (SSc-ILD), resistant to aggressive treatment regimens, provided further evidence for the efficacy of CD19 CART cells [54].